leadf
logo-loader
viewAvacta Group PLC

Avacta's Alastair Smith updates on selection of cancer candidate to take into clinic

Avacta Group PLC's (LON:AVCT) Alastair Smith tells Proactive London's Andrew Scott they've selected the cancer drug candidate they'll be taking into first-in-human clinical trials.

It's an important step for the company as it means they remain on track to submit an investigational new drug/clinical trial application by the end of next year.

Quick facts: Avacta Group PLC

Price: 126.99 GBX

AIM:AVCT
Market: AIM
Market Cap: £320.84 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Ora Banda Mining anticipating its first gold bar by the end of January

Ora Banda Mining Ltd's (ASX:OBM) David Quinlivan talks Proactive's Andrew Scott through its December quarterly update. He says they've now begun wet commissioning of the plant and will be progressively commissioning over the coming weeks with a view of getting the first gold bar out by the end...

5 hours, 46 minutes ago

2 min read